Eli Lilly (LLY -0.4%) is halting the Phase III trial of its tabalumab drug in patients with...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY -0.4%) is halting the Phase III trial of its tabalumab drug in patients with rheumatoid arthritis, due to insufficient efficacy. However, Lilly will continue two other Phase III studies, which are testing tabalumab for systemic lupus erythematosus, an autoimmune disease. Tabalumab's failure adds to that for AsraZeneca's fostamatinib, and follows a blow for Lilly's solanezumab treatment for Alzheimer's. (PR)